FDA has ramped up its enforcement of cosmetic claims that trespass on drug turf, but the most significant threat to businesses continues to be the potential for class actions that frequently piggyback on enforcement actions and other issues brought to the public’s attention, attorney Steve Shapiro says.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on HBW Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?